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Abstract: Congenital PAX6-aniridia is a rare panocular disease resulting from limbal stem cell defi-
ciency. In PAX6-aniridia, the downregulation of the retinol-metabolizing enzymes ADH7 (All-trans-
retinol dehydrogenase 7) and ALDH1A1/A3 (Retinal dehydrogenase 1, Aldehyde dehydrogenase
family 1 member A3) have been described in limbal epithelial cells (LECs) and conjunctival epithelial
cells. The aim of this study was to identify the role of retinol derivates in the differentiation of human
LEC and its potential impact on aniridia-associated keratopathy development. Human LEC were
isolated from healthy donor corneas and were cultured with retinol, retinoic acid, or pan-retinoic acid
receptor antagonist (AGN 193109) acting on RARα, β, γ (NR1B1, NR1B2 NR1B3) or were cultured
with pan-retinoid X receptor antagonist (UVI 3003) acting on RXR α, β, γ (retinoid X receptor, NR2B1,
NR2B2, BR2B3). Using qPCR, differentiation marker and retinoid-/fatty acid metabolism-related
mRNA expression was analysed. DSG1 (Desmoglein 1), KRT3 (Keratin 3), and SPINK7 (Serine Pepti-
dase Inhibitor Kazal Type 7) mRNA expression was downregulated when retinoid derivates were
used. AGN 193109 treatment led to the upregulation of ADH7, KRT3, and DSG1 mRNA expression
and to the downregulation of KRT12 (Keratin 12) and KRT19 (Keratin 19) mRNA expression. Retinol
and all-trans retinoic acid affect some transcripts of corneal LEC in a similar way to what has been
observed in the LEC of PAX6-aniridia patients with the altered expression of differentiation markers.
An elevated concentration of retinol derivatives in LEC or an altered response to retinoids may
contribute to this pattern. These initial findings help to explain ocular surface epithelia differentiation
disorders in PAX6-aniridia and should be investigated in patient cells or in cell models in the future
in more detail.
Keywords: aniridia; retinoic acid; PAX6; limbal epithelial cells; DSG1; ADH7; aniridia-associated
keratopathy (AAK)
1. Introduction
Retinoids act through nuclear receptors at the transcriptional level; however, the non-
receptor-mediated functions of retinoids have not been extensively studied as of yet [1].
Besides their important role in development, retinoids also have the capability to affect
apoptosis, the differentiation and proliferation of skin epidermal cells [2], as well as to
affect the apoptosis, proliferation, surface wound healing, and keratinization of corneal
epithelial cells [1,3]. A severe vitamin A deficiency leads to xerophthalmia (dry eye) and
keratopathy [4].
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All-trans retinoic acid (at-RA) acts through binding to the retinoic acid-receptors RAR
α, β, γ (NR1B1, NR1B2 NR1B3), RXR α, β, γ (retinoid X receptor, NR2B1, NR2B2, NR2B3),
and PPARα, β/δ, γ (peroxisome proliferator-activated receptors NR1C1, NR1C2, NR1C3).
Patients with a haploinsufficiency of the PAX6 (Paired box protein Pax-6) gene
(PAX6+/-) suffer from complete or partial absence of the iris tissue and corneal opaci-
fication and vascularization due to a limbal stem cell deficiency and several other ocular
and systemic pathologies. An abnormal epidermal- (skin) like phenotype of the corneal
epithelium is associated with severe ocular surface disease in congenital aniridia. These
changes in the corneal epithelium are associated with PAX6 downregulation [5].
PAX6 is a transcription factor and has been shown to physically interact with various
transcription factors such as c-Maf (Transcription factor Maf), Sox2 (transcription factor
SOX-2), TFIID (transcription factor II D), pRb (retinoblastoma-associated protein), and MitF
(microphthalmia-associated transcription factor) [6]. A physical or functional relationship
between PAX6 and at-Ra has been investigated in the regulation of crystalline genes. The
multifactorial enhancer elements in crystalline promotor regions have binding sites for
PAX6 and RARs, which bind cooperatively and regulate gene expression [7]. In Pax6
knockout mice, surface ectoderm-derived structures are unable to respond to retinoic acid
after embryonic stage E9. Therefore, PAX6 is important for responding to at-RA in surface
ectoderm-derived structures [8].
We have evidence that retinoic acid signaling may also be impaired in aniridia-
associated keratopathy. The regulation of the transcriptional genes involved in the enzy-
matic conversion of retinoids as well as in retinoid- and fatty acid signaling is different in
aniridia patient-derived ocular surface cells. These genes include ADH7 (all-trans-retinol
dehydrogenase 7), ALDH1A1 (retinal dehydrogenase 1), ALDH3A1 (aldehyde dehydro-
genase, dimeric NADP-preferring), PPARG (peroxisome proliferator-activated receptor
gamma), FABP5 (fatty acid-binding protein 5), CYP1B1 (cytochrome P450 1B1), CYP26A1
(cytochrome P450 26A1), STRA6 (receptor for retinol uptake STRA6), and RDH10 (retinol
dehydrogenase 10) [9,10].) The complex interactions between PAX6 and various transcrip-
tion factors, including retinoid acid signaling, makes it difficult to interpret the expression
profiles from aniridia subjects in order to identify the pathophysiological principles of the
phenotypic changes of the corneal epithelium and the subsequent corneal opacification.
The expression changes observed in patients could have different explanations. PAX6
might control the genes involved in retinoid metabolism directly, thereby changing the
concentrations of active compounds such as at-RA in the cells. Additionally, PAX6 may
possibly synergistically act with retinoic acid receptors during gene expression. This might
also impact the genes needed for retinoid metabolism.
By manipulating genes at-RA levels, we sought to identify the genes that are related
to the differentiation processes that are under the control of retinoic acid receptors or that
are partly regulated by retinoic acid receptors.
Since the effect of retinoids at the transcription level has not been studied on limbal
epithelial cells so far, we provided the first profile of a set of transcripts to generate an
idea as to what extent retinoic acid metabolism and signaling could influence AAK-related
expression profiles or which transcripts are sensitive to at-RA treatment.
Limitations: The experimental design of this study was not able to gain mechanistic
insight into how PAX6 and retinoic acid directly interact with each other and how these
effect the expression of their downstream genes. While working with primary cells with
limited availability and low dividing capacity, it was also not possible to observe putative,
short-term expression changes or PAX6 regulation in this setting.
2. Materials and Methods
Ethical considerations: The use of patient tissue in this study was approved by the
Ethical Committee of Saarland/Germany (no. 226/15).
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2.1. Cell Cultures and Treatment
Limbal tissue of healthy corneal donors was punched out using a 1.5 mm biopsy
punch. The tissue was incubated with 500µL collagenase A (Roche Pharma AG, Basel,
Switzerland) for 24 h at 37 ◦C. Primary limbal epithelial cell (LEC) clusters were filtered and
were dissolved with 2.5 mL trypsin-EDTA-solution (Sigma-Aldrich GmbH, Deisenheim,
Germany). Then, LEC were resuspended in 500 µL keratinocyte serum free medium
(KSFM; Gibco, Carlsbad, CA, USA) and were seeded in one well of a 24-well plate. U LEC
were incubated at 37 ◦C until confluence was reached. Thereafter, to transfer the LEC into
a 6-well-plate, the cells were trypsinated and were dissolved in 3 mL of KSFM (Gibco,
Carlsbad, CA, USA). The cells were passaged three times.
After growing to confluence in four 6-wells, each individual LEC culture was treated
for 24 h with 0.5 µM or 1.5 µM retinol (Ret) or all-trans-retinoic acid (at-RA), respectively.
The concentration used for the 48 h treatment was 1 µM or 5 µM retinol (Ret) or all-trans-
retinoic acid (at-RA) (Sigma-Aldrich GmbH). Moreover, the LECs were treated for 24 h or
48 h with 0.5 µM, 1.0 µM, or 1.5 µM of RAR antagonists (AGN 193109) or 0.5 µM, 1.0 µM,
or 1.5 µM of RXR antagonists (UVI 3003) (Sigma-Aldrich GmbH). Ret, at-RA, AGN 193109,
and UVI 3003 were dissolved in dimethylsulfoxid (DMSO) and were diluted in KSFM to
reach the above concentrations. The control cultures were treated using DMSO during the
same incubation periods. Each treatment and each incubation time (24 h/48 h; Ret, at-RA,
AGN, and UVI) was repeated three times with individual limbal epithelial cultures from
different donors. The incubation happened under the same conditions as the cell culture
procedures described above.
2.2. XTT Assay
Cell viability was evaluated using the XTT assay as follows: human LECs were seeded
into 96-well cell culture plates in KSFM. After reaching 70% confluence, the culture medium
was changed to a culture medium containing either 0.1 µM, 0.5 µM, 1 µM, or 5 µM retinol
(Ret), all trans-retinoic acid (at-RA), AGN 193109 (AGN), or UVI 3003 (UVI) for 24 h and
48 h, respectively. Then, freshly prepared XTT solution was added to each well. As a
negative control, XTT solution was added to a well without cells. After an incubation
period of 30–60 min, absorbance was measured at 550 nm using a 96-well microplate reader
(TECAN Infinite F50).
2.3. RNA/Protein Extraction and cDNA-Synthesis
RNA and protein were extracted using the RNA/DNA/Protein Purification Plus
Micro Kit (Norgen, Thororld, ON, Canada) following the standardized protocol. The RNA-
concentration was measured by means of UV/VIS-spectrophotometry (NanoDrop 1000
Spectrophotometer, Thermo Fisher Scientific, Waltham, MA, USA). For protein concentra-
tion measurements, a standardized Bradford test (Sigma-Aldrich GmbH) was conducted.
The cDNA-synthesis was performed using the OneTaq RT-PCR Kit (New England BioLabs,
Frankfurt a.M., Germany). An amount of 500 ng of RNA was used for one reaction (50 µL
of the cDNA-synthesis).
2.4. Quantitative Polymerase Chain Reaction (qPCR)
For the qPCR, 1.25 µL Primer (Table A1 Appendix A) (QIAGEN GmbH, Hilden,
Deutschland), 5µL AceQ SYBR qPCR Master Mix (Vazyme Biotech, Nanjing, China),
and 0.5 µL cDNA were pipetted into one well of a 96-well plate according to the AceQ
SYBR qPCR Kit (Vazyme Biotech, Nanjing, China). Beta-glucuronidase (GUSB) and TATA-
binding-protein (TBP) were used as reference genes. From the Ct value and the calculated
∆Ct and ∆∆Ct values, the fold change (2∆∆Ct) was calculated. The following steps were
repeated 40 times: initial denaturation to 95 ◦C for 5 min, denaturation at 95 ◦C for 10 s,
and primer hybridization at 60◦ for 30 s. Elongation occurred when the sample was being
heated up for the denaturation phases. The software QuantStudio™ Design & Analysis
(Thermo Fischer, Waltham, MA, USA) was used for evaluation.
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2.5. PAX6 Immunfluorescence Staining
To measure putative PAX6 protein expression changes, the LECs of three different
donors were seeded into 96-well cell culture plates, and the cells were grown to 70%
confluence. Individual wells were treated with DMSO (Ctrl) or with 0.1 µM, 1 µM, 1.5 µM,
or 5 µM retinol (Ret), all trans-retinoic acid (at-RA), AGN 193109 (AGN), or UVI 3003 (UVI)
for 24 h and 48 h, respectively.
During each step, the treatments were mixed in a total volume of 50 µL per well. After
reaching confluence, the cells were directly fixed in 96-wells with 4% paraformaldehyde
(PFA; PZN 2653025, Fischar). Cells were permeabilized with ice cold pure methanol for
5 min. Nonspecific epitopes were blocked with Phospahte buffered saline (PBS) containing
5% fetal calf serum (FCS) and 0.3% Triton-X-100 for 2 h. Primary antibodies were diluted
in PBS containing 1% FCS and 0.1% Triton-X-100. For staining, mouse anti-PAX6 antibody
(Santa Cruz, sc-32766, 1:50) was incubated overnight at 4 ◦C. Cells were washed three
times with PBS containing 0.05% Tween. The secondary antibody, anti-mouse AF555 (Life
Technologies, Cat. No. A21422), was diluted at a ration of 1:200 in washing buffer. After
1.5 h of incubation at room temperature, the cells were washed three times again, and the
nuclei were stained with DAPI (Sigma, Cat. No. D9542). Cells were kept in PBS until image
aquisition. Images were acquired with a Nikon Eclipse 100 microscope (Nikon, Japan)
equipped with a 20× objective and suitable filter sets (DAPI, DAPI; Alexa 555, Cy3). For
each treatment, two images were processed with ImageJ software. To compare the control
LECs and treated cells, exposure times and image processing (e.g., brightness adjustments)
were performed identically. For semi-quantitative analysis, nuclei were identified using
DAPI staining, and ROIs were defined with ImageJ Software; then, the mean integrated
grey values for each cell were measured in the PAX6 (Cy3) channel. The total PAX6 intensity
of the controls was set to 100%, and the signals were normalized to this value, and these
were compared to those in the treated cells.
2.6. Statistical Analysis
For all of the treatment types (Ret, at-RA, AGN, UVI), viability and mRNA expression
values (∆∆Ct values) were compared to the controls using one-way ANOVA followed by
Dunnett’s multiple comparisons test. Analysis was performed with GraphPad Prism 7.04
software (SanDiego, CA, USA).
3. Results
In the primary limbal epithelial cell cultures in vitro, the highest proportion of the cells
belonged to transient amplifying cells. In vivo, at the corneal surface, these cells would
further differentiate into mature corneal epithelial cells. This differentiation process is
limited in cell culture, but could be triggered by air-lift culture, etc. Nevertheless, changes
in differentiation marker expression are already measurable in LEC cultures, and these
can be useful in identifying factors influencing differentiation at the gene expression level.
As a first step, we started to investigate the possible adverse effects of different treatment
options on LECs.
At-RA treatment for 24 h led to a minor but significant increase in viability at all
concentrations, whereas 5 µM UVI led to a dramatic, significant decrease of cell viability.
The same was true for the 48 h treatment using 5 µM AGN or UVI. There was no significant
effect resulting from any of the other treatments on LEC viability, which was measured
with the XTT assay (Figure 1).
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PAX6-evoked expression changes, PAX6 mRNA and protein expression measurements 
after at-RA and Ret treatment was necessary. The 24 h Ret treatment showed a significant 
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Figure 1. XTT viability assay of primary LEC treated with retinol (Ret), all trans-retinoic acid (at-RA), AGN 193109 (AGN),
or UVI 3003 (UVI) for 24 h and 48 h at increasing concentrations (controls without treatment) of 100 nM, 500 nM, 1 µM,
1.5 µM, 5 µM), respectively. * p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001; n = 3.
MKI67 was used as a cell proliferation marker. MKI76 mRNA expression is the highest
in the M Phase of the cells [11,12]; therefore, it could also be used as a proliferation marker.
Retinol (Ret) had no significant impact on MKI67 expression at any of the incubation
times (Figure 2). At-RA treatment for 24 h also did not influence MKI76 mRNA expression
when using any of the concentrations. After at-RA treatment for 48 h, there was a signif-
icant decrease in MKI67 mRNA expression when using the 1 µM (FC = 0.46) and 5 µM
concentrations (FC = 0.001). AGN treatment for 24 h and 48 h led to significant MKI67
downregulation at the 1.5 µM concentration (FC < 0.2), and there was a less pronounced
downregulation at lower concentrations. Nevertheless, 1.0 µM AGN treatment for 48 h
showed no significant fold change reduction. UVI treatment for 24 h evoked significant
MKI67downregulation when using the 1.0 µM (FC = 0.49) and 1.5 µM concentrations
(FC = 0.16).
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Figure 2. qRT-PCR analysis of the proliferation marker MKI67 (Ki67) in primary limbal epithelial cells treated with retinol
(Ret), all trans-retinoic acid (at-RA), AGN 193109 (AGN), or UVI 3003 (UVI) for 24 h and 48 h. Expression fold changes (FC)
were calculated relative to each control with the ∆∆Ct method. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; n = 3.
As the aim of our study was to separate the response of at-RA from previously known
PAX6-evoked expression changes, PAX6 mRNA and protein expression measurements
after at-RA and Ret treatment was necessary. The 24 h Ret treatment showed a significant
but minor increase at the PAX6 mRNA level when using the 0.5 µM (FC = 1.2) and 1.5 µM
Ret concentrations (FC = 1.2). There was a significant PAX6 mRNA downregulation when
using the 1 µM (FC = 0.7) and 5 µM (FC = 0.6) concentrations in the at-RA treatment
group after 48 h but not after 24 h, whereas neither AGN and UVI treatment nor any
Biomolecules 2021, 11, 1651 6 of 17
other conditions changed PAX6 mRNA expression (Figure 3A). In contrast, no significant
difference in nuclear PAX6 staining was observed at any time points or concentrations
compared to the controls (Figure 3B).
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(set as 100%). * p ≤ 0.05; ** p ≤ 0.01; n = 3.
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DSG1 (Desmoglein-1) is a cellular junction protein, and it has been reported to be
downregulated in Sey+/− (Pax6+/−) mice, which is an animal model for congenital aniridia.
DSG1 expression was also downregulated in anirida patient-derived ocular surface cells
when the siRNA-based PAX6 knockdown cell model was used [10,13]. SPINK7 is a protease
inhibitor of kallikrein serine proteases (KLKs), which are also able to cleave DSG1, for
example [14]. SPINK7 was found to be downregulated in our siRNA-based aniridia cell
model (artificial PAX6 knockdown in LECs) as well [10]. It remains unclear how these
genes are regulated in limbal epithelial cells.
DSG1 mRNA expression tended to result in a reduction after 24 h Ret incubation, and
DSG1 expression was significantly reduced after 48 h when using the 1 µM (FC = 0.06)
or 5 µM (FC = 0.06) Ret concentrations. The treatments using the 1 µM or 5 µM at-RA
concentrations also led to reductions in DSG1 (FC = 0.07 and FC = 0.3). In contrast, after
treatment with the RAR antagonist AGN, DSG1 was upregulated after 24 h at all of the
tested concentrations (0.5 µM (FC = 2.1); 1.0 µM (FC = 3.5); 1.5 µM (FC = 3.2)). The
upregulation after the 48 h AGN incubation was not significant. DSG1 mRNA expression
did not change significantly upon UVI treatment (Figure 4). SPINK7 mRNA expression
did not decrease after the 24 h Ret treatment but decreased significantly after the 48 h Ret
treatment with the 1 µM (FC = 0.3) or 5µM concentrations (FC = 0.3). The 24 h incubation
with at-RA led to significant SPINK7 downregulation when using the 0.5 µM (FC = 0.52)
and 1.5 µM concentrations (FC = 0.52) and to an even more prominent SPINK7 reduction
after the 48 h at-RA treatment with the 1 µM (FC = 0.2) or 5 µM concentrations (FC = 0.1).
AGN and UVI treatment had no significant impact on SPINK7 expression (Figure 4).
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Figure 4. qRT-PCR analysis of DSG1 and SPINK7 transcripts in primary limbal epithelial cells (LEC) treated with retinol
(Ret), all trans-retinoic acid (at-RA), AGN 193109 (AGN), or UVI 3003 (UVI) for 24 h and 48 h. The transcripts shown here
are related to the PAX6+/− phenotype in patients and cell models. Expression fold changes (FC) are calculated relative to
each control using the ∆∆Ct method. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; n = 3.
Keratins are important differentiation markers of the ocular surface. Their relative
expression in LECs compared to differentiated corneal epithelial cells is very low. KRT3
and KRT12 markers are downregulated in ocular surface of subjects with aniridia and are
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described as being regulated by PAX6 in vitro as well [15,16]. However, further signals
may be needed to better specify corneal cell identity. KRT19 is regarded as a conjunctival
marker.
KRT3 mRNA expression was downregulated after the 48 h Ret treatment using the
1.0 µM (FC = 0.47) and 1.5 µM concentrations (FC = 0.49) but not after the 24 h incubation
time (Figure 5). The 24 h Ret treatment showed an upregulation trend instead. There were
no significant expression changes when using the at-RA treatment for 24 h or for 48 h. AGN
and UVI did not show a significant effect on KRT3 expression. KRT12 was significantly
upregulated after the 24 h Ret treatment using the 1.5 µM concentration (FC = 1.4) and after
48 h with the 1 µM Ret treatment (FC = 1.7). A similar pattern was observed after the at-RA
treatment, with a KRT12 upregulation occurring when the 1.5 µM concentration (FC = 1.7)
was used after 24 h (Figure 5). After the 48 h at-RA treatment, a KRT12 upregulation at
the 1 µM concentration (FC = 2.8) was observed. AGN treatment for 24 h (FC = 0.5–0.7)
and 48 h (FC = 0.3–0.7) led to a significant KRT12 downregulation when using all of the
concentrations. UVI treatment did not lead to significant changes.
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Figure 5. qRT-PCR analysis of KRT3, KRT12, and KRT1 cripts in primary limbal epithelia cells (LEC) treated with
retinol (Ret), all trans-retinoic acid (at-RA), GN 193109 (AGN), or UVI 3003 (UVI) for 24 h and 48 h. The transcripts shown
here are related to the corneal (KRT3/KRT12) and limbal/conjunctival epithelial phenotype (KRT19). Expression fold
changes (FC) are calculated relative to each control using the ∆∆Ct method. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; n = 3.
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KRT19 mRNA expression was only significantly upregulated after the 48 h at-RA
treatment when using the 5 µM concentration (FC = 2.9). KRT19 downregulation following
AGN treatment was observed after 24 h when using the 0.5 µM (FC = 0.6) and 1.0 µM AGN
concentrations (FC = 0.7).
Enzymes and components of retinol and fatty acid metabolism (ADH7, ALDH1A1,
RBP1, RDH10, CRABP2, ELOVL7, FABP5, and PPARG) were altered on the ocular surface
cells from aniridia patients and in the siRNA-based aniridia cell model. Our purpose
was to monitor the gene expression changes of these genes in response to at-RA and pan-
RAR and pan-RXR antagonists. This should allow us to draw conclusions regarding the
observed expression patterns in the cells of aniridia subjects and in aniridia cellular models
are affected by retinoid metabolism and which pathways are likely involved. Several
transcripts were significantly altered upon treatment: See the results of transcripts ADH7,
ALDH1A1, RBP1, RDH10, and CRABP2 (Figure A1) and the results of ELOVL7, FABP5,
and PPARG (Figure A2). However, no clear conclusions/metabolic linkages could be
drawn from these transcriptional results (See discussion for further interpretation and
limitations).
4. Discussion
4.1. Effect of Retinol and Retinoic Acid on MKI67 Expression
The effect of retinol and at-RA on differentiation and proliferation has been studied
by several research groups previously, who have analysed limbal epithelial cells and skin
epidermal cells [17–19]. The 1 µM at-RA dosage used in this study has been reported to
prevent abnormal differentiation and to reduce colony forming efficiency (measures of
high proliferative stem cells) [20]. The highly significant downregulation of MKI67 mRNA
expression (Figure 2) is in line with the decrease of colony forming efficiency in limbal
epithelial cells upon at-RA treatment, as reported by others.
4.2. Effect of Retinol and Retinoic Acid on LEC
Retinol evoked similar effects on limbal epithelial cell mRNA expression to those of
at-RA treatment for some of the transcripts in our present study. This could be explained by
the simple conversion of retinol to at-RA in corneal epithelial cells. For some experiments
(DSG1), there was a weaker or no response after 24 h compared to after the 48 h Ret
treatment (DSG1, SPINK7 and KRT3), which could partly be explained by the fact that
Ret first needs to be converted to at-RA in the LECs. The presence of all of the enzymatic
components converting retinol to active at-RA in corneal epithelial cells and the enzymatic
conversion of retinol to at-RA has been previously observed in corneal tissue [21].
4.3. Similarities and Differences in RA Signaling and PAX6 Haploinsufficiency
PAX6 and retinoid signaling have already been linked previously, but these were
mostly discussed and observed in the developmental processes of the eye and brain [8,22].
In neurons, PAX6 is reported to be upregulated by at-RA, although the PAX6 promotor does
not contain functional retinoic acid response elements [22]. In PAX6−/− rats, ALDH1A3
is not expressed, and it has been speculated that ALDH1A3 (RALDH-3) is a downstream
target of PAX6 [23].
In prior experiments, we observed an enrichment of deregulated genes that are
associated with retinoid metabolism in PAX6+/- epithelial cells that had been derived
from patients and in cellular models. For example ADH7, ALDH1A1, and ALDHA1A3 are
downregulated in PAX6+/−-derived patient cells [9,10]. Since ADH7 can oxidize retinol
to its aldehyde form [24,25] and since ALDH1A1/3 are enzymes that can oxidize retinol
to retinoic acid [26], we speculated, that a part of the expression changes that have been
observed in cellular models and in patient cells are related to a deficient at-RA metabolism.
Our hypothesis was that a locally reduced at-RA concentration may lead to an impaired
differentiation of primary LEC.
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In addition to the changes in RA-associated transcripts, differentiation makers of the
corneal epithelium such as DSG1 are downregulated in aniridia mouse models and upon
PAX6 knockdown in primary corneal epithelial cells [13,27].
In order to make sure that the effect of at-RA on gene expression is not through the
feedack of at-RA on PAX6 expression, we analysed to what extent at-RA influences PAX6
expression. The treatment of primary limbal epithelial cells with Ret for 24 h provoked a
slight increase of PAX6 mRNA expression, and 48 h of at-RA treatment was related to a
downregulation of PAX6 mRNA. With the immunfluoresence imaging of nuclear PAX6
staining, we did not detect an effect of Ret treatment on the PAX6 protein level under
any treatment condition (Figure 3B). One should consider that we did not determine any
dynamic changes in the PAX6 protein level over time. Since posttranslational regulation or
narrow time scaling could not be included in our experimental setup, a small amount of
uncertainty regarding a putative influence of RA on PAX6 protein level remains.
Therefore, to the best of our knowledge, the administration of Ret and at-RA to
the LECs of healthy donors could influence differentiation marker expression that is
independent of PAX6. At-RA decreased SPINK7 and DSG1 mRNA expression (Figure 4),
supporting evidence that some expression changes observed in aniridia patients are likely
due to the overactivation of retinoic acid signaling or the accumulation of at-RA. These
expression changes were similar to the changes observed in aniridia corneal epithelial cells
and upon the PAX6 siRNA knockdown of LEC (See Table 1).
Table 1. mRNA expression changes in limbal epithelial cells (LEC) following treatment and in aniridia patient cells.
Transcripts with similar behaviour through retinol (Ret)/all trans-retinoic acid (at-RA) stimulation and in aniridia-related
models or primary limbal epithelial cells (LEC) are highlighted in green. Transcripts with unexpected response in one of the
cellular systems are highlighted in yellow. Transcripts not reacting according our hypothesis are not highlighted. RAR:
retinoic acid receptor; siPAX6: siRNA based cell model with PAX6 knockdown; 1 = primary LECs from aniridia subjects;
2 = primary LECs from healthy subjects treated with siRNA against PAX6; “—” = no data available; * = unpublished Data.










ADH7 DOWN (n.s) UP DOWN 1/DOWN 2 DOWN
DSG1 DOWN UP DOWN 1/DOWN 2 DOWN
SPINK7 DOWN No change DOWN 1/DOWN 2 —
ALDH1A1 No change No change DOWN 1/DOWN 2 —
KRT12 UP DOWN DOWN 1/No change 2 —
KRT3 DOWN UP DOWN 1/DOWN 2 —
KRT19 UP DOWN — 1/— 2 —
ELOVL7 UP UP UP 1/No Change * UP
FABP5 No Change UP DOWN 1/DOWN * DOWN
PPARG Unclear UP UP 1/DOWN * UP
CRABP2 DOWN UP DOWN 1/DOWN * UP
RBP1 UP No change No change 1/DOWN * UP
RDH10 UP UP No change 1/DOWN * UP
DSG1 expression is a very stable readout for PAX6 defienceny conditions in differ-
entiating ocular surface cells. DSG1 is downregulated in Sey+/− (PAX6+/−) mice [13], in
primary corneal epithelial cells upon complete PAX6 knockout [27], in ocular surface ep-
ithelial cells of human anridia patients, and upon the siRNA knockdown of the primary
limbal epithelial cells of healthy donors [10].The data from the present study indicate that
DSG1 downregulation happens due to a disturbed retinol metabolism and that DSG1 is
not directly regulated by PAX6. The evidence for this would be as follows:
Treatment with retinol as well as with at-RA leads to a significant and sustained
downregulation of DSG1 mRNA. Admission of the AGN antagonist (RAR receptor antag-
onist) led to a DSG1 mRNA expression increase (Figure 4). This observation was similar
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in skin epidermal cells, as at-RA led to the downregulation of DSG1 mRNA and protein
expression [28].
A similar argumentation could be also true for SPINK7. SPINK7 was identified to be
potentially regulated by PAX6 in our own previous screening [10]. It may inhibit Kallikrein
serine proteases (KLKs), which are able to cleave, e.g., DSG1 [14]. Therefore, a functional or
regulatory relationship to DSG1 is conceivable. SPINK7 was downregulated in the samples
stimulated with Ret and at-RA, but no clear upregulation by AGN antagonist was observed.
SPINK7 may be affected due to the changes in at-RA signaling rather than being a direct
downstream target of PAX6.
The underlying mechanisms of the regulation of keratins could not be presented
as clearly. Several keratins are well-described selective differentiation markers for the
corneal epithelium. Their altered expression pattern upon severe ocular surface disease
includes the loss of KRT12 and KRT3 expression [5]. In contrast to the other investigated
markers in this study, corneal keratins have been linked to PAX6 expression by several
other groups [16]. PAX6 protein expression is necessary for KRT12 mRNA and protein
expression, but PAX6 protein alone is not sufficient for its expression, as shown by promotor
analysis [15,29]. CRISPR/CAS-mediated PAX6 knockout in corneal epithelial cells resulted
in strong KRT12 and KRT3 downregulation [27].
Analysing in vitro or in vivo, several keratins have diverse responses to at-RA treat-
ment in case of the skin [30]. Although keratin expression is influenced by at-RA, the
RAR/RXR receptors are not involved in the regulation of all keratins since the retinoid
response elements (RAREs) cannot be found in the keratin promotor region of KRT2 and
KRT4, for example [30].
Only a few of the tested conditions in our study showed the upregulation of KRT12
and the downregulation of KRT3 in the transcriptional data. However, Kim et al. described
KRT12 protein upregulation and KRT3 protein downregulation using a 1 µM at-RA treat-
ment in stratified corneal epithelial sheets [17]. The alterations in keratin mRNA expression,
which were also described in our study, match these previous observations [17]. Since our
results are not clear concerning the influence of at-RA on KRT expression, this may point to
a limitation of our study: it is impossible to extrapolate the observed but minor expression
changes to biological means during differentation processes.
An upregulation of KRT19 mRNA expression upon at-RA stimulation has been re-
ported in several studies, especially those analysing skin epidermal cells in vitro and
in vivo. In LECs, in our present study, only the 48 h at-RA stimulation with a high concen-
tration evoked an upregulation. It has been shown by others that KRT19 mRNA elevation
is not a consequence of enhanced mRNA transcription but instead happens due to the
posttranslational stabilization of the transcript [31]. Significant KRT19 mRNA downregula-
tion (FC > 0.6) after 24 h with RAR antagonist treatment may be due to revertion of the
unknown mechanism of mRNA stabilization.
In conclusion, a minor impact of at-RA treatment on keratin expression can be ob-
served in LECs. The role of at-RA in the regulation of keratins and its role in AAK
pathogenesis cannot be be drawn from in vitro LEC data in this study.
4.4. RA Transport, Metabolism and Signaling/Transcripts Involved in Fatty Acid Metabolism
and/or Signaling
In contrast to the relative clear changes in DSG1, SPINK7, or keratin expression pat-
terns, ADH7, ALDH1A1, RBP1, RDH10, and CRABP2 expression (Figure A1) or ELOVL7,
FABP5, and PPARG expression (Figure A2) did not show clear trends as a response to
Ret or at-RA treatment. The responses were often restricted to one concentration of the
experimental series. In addition, the response to the antagonists was not specific; therefore,
we were unable to assign the response to a retinoic acid receptor class. This might be due
to following reasons or experimental limitations:
When applying higher concentrations of at-RA, there is also a risk for activating
cis-RA-related signaling, as cis-RA is always present as an unavoidable contamination in
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at-RA solutions and could lead to over-activation of the RXR-RAR heterodimer [32]. In
addition, UVI can transactivate PPARG at higher concentrations [33].
Extensive titration of the concentations helps to avoid cross activity and supports the
use of more specific agonists and antagonists. However, there is then a demand for an
extensive use of primary or other cells. As these are not available, other tools beyond drug
treatment should be prefered in the future to study the impact of at-RA signaling on gene
expression in limbal epithelial cells.
Expression of retinoic acid binding proteins CRABP2, RBP1, and retinol dehydroge-
nase RDH10 may change as a response to altered retinoid levels or may be influenced by
activated RAR and RXR receptors.
ADH7 mRNA expression, in contrast to the siRNA experiments reported by us, was
not significantly regulated when at-RA was administered alone, but followed the same
trend for some concentrations after 48 h with the 1 µM Ret or 1 µM at-RA treatment.
Nevertheless, when using a higher Ret or at-RA dosage, the changes were even less
pronounced (Figure A1). RAR and RXR activation both might suppress ADH7 expression,
but a transactivation of PPARG through the used high antagonist concentrations could also
interfere with the regulation of AHD7.
ADH7 enzymatic activity is not only restricted to retinoids but is also restricted to
medium chain fatty acids (MCFs). Therefore, we also checked the deregulated transcripts
in the fatty acid metabolism.
Changes in FABP5, PPARG, and ELOVL7 transcription, which are often observed in
anirida, could be explained through the crosstalk of fatty acids with retinoic acid signaling.
Responses of these latter-mentioned transcripts to at-RA could give valuable hints for such
a crosstalk. FABP5 and PPARG may both effect at-RA and fatty acid (FA) signaling [34,35],
and ELOVL7 is related to fatty acid metabolism [36]. ELOVL7 and PPARG were signifi-
cantly upregulated after the 24 h und 48 h AGN treatments. After the UVI treatment, gene
expression tended to be similar. The regulation of these transcripts could be influenced by
other sensors that are able to recognise the lipophilic molecular structure of the molecules
that were used for treatment in the present study rather than RAR/RXR receptors, which
were the actual target of the treatment. Therefore, the observed ELOVL7, FABP5, and
PPARG transcriptional changes in aniridia patient cells cannot be based on a simple change
in the at-RA metabolism but are related to more complex changes in cellular signaling
pathways.
The functional balance between at-RA and fatty acid metabolism and signaling could
be important to maintain an ocular surface epithelial phenotype without keratinization and
cornified envelope formation. However, such a connection to at-RA signaling could not be
established in our in vitro systems, which only anlaysed the short-term impact of at-RA
concentration changes, although the ELOVL7, FABP5, and PPARG transcripts responded to
at-RA and AGN.
Summarizing all of the described data, we conclude that the influence of Ret or at-RA
on gene expression in aniridia LECs exists independently from direct changes in PAX6
mRNA or protein expression. Our in vitro data suggest that an elevated Ret or at-RA level
correlates with reduced DSG1 and SPINK7 mRNA expression, and some concentrations
probablyt evoke reduced ADH7 expression. In the corneal and conjunctival epithelial cells
of PAX6+/- patients, DSG1, ADH7, and probably SPINK7 downregulation could be evoked
by elevated Ret or at-RA levels. A more global regulation of at-RA signaling that could
interfere with changes in PAX6 expression is likely involved but is not adressed in the
presented data.
At-RA signaling, which influences tissue-specific controled genes, is not understood
in detail. The binding of RAR and RXR to specific promotor regions and associated
chromatin remodeling as well as crosstalk to other signals such as FGF/MAPK, TFGβ/BMP,
hedgehog, Notch Wnt, and Jak/STAT pathways are reported in other systems that are
already separate from the eye [37]. Therefore, a more detailed proteomic and metabolic
data analysis obtained from patient epithelial cells is necessary in the future.
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5. Conclusions
Despite the limitations of our in vitro systems and the restrictions for transcriptional
analysis, we were able to provide supporting data that retinoic acid signaling impacts
several transcripts that are markers for corneal epithelial differentiation. These include
DSG1, SPINK7, and to lesser extent, the Keratins KRT12 and KRT3.
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Appendix A
Table A1. qPCR primers used in our experiments.
Primer Catalog Number Amplification Size (bp) Manufacturer
ABCG2 QT00073206 114 bp QIAGEN GmbH, Hilden, Germany
ADH7 QT00000217 85 bp QIAGEN GmbH, Hilden, Germany
ALDH1A1 QT00013286 97 bp QIAGEN GmbH, Hilden, Germany
ALDH3A1 QT02401931 121 bp QIAGEN GmbH, Hilden, Germany
CRABP2 QT00063434 140 bp QIAGEN GmbH, Hilden, Germany
CYP1B1 QT00209496 114 bp QIAGEN GmbH, Hilden, Germany
DSG1 QT00001617 96 bp QIAGEN GmbH, Hilden, Germany
ELOVL7 QT01025976 89 bp QIAGEN GmbH, Hilden, Germany
FABP5 QT00225561 97 bp QIAGEN GmbH, Hilden, Germany
GUSB QT00046046 96 bp QIAGEN GmbH, Hilden, Germany
Ki67 QT00014203 86 bp QIAGEN GmbH, Hilden, Germany
KRT12 QT00011949 104 bp QIAGEN GmbH, Hilden, Germany
KRT19 QT00081137 117 bp QIAGEN GmbH, Hilden, Germany
KRT3 QT00050365 118 bp QIAGEN GmbH, Hilden, Germany
PAX6 QT00071169 113 bp QIAGEN GmbH, Hilden, Germany
PPARG QT00029841 113 bp QIAGEN GmbH, Hilden, Germany
RBP1 QT01850296 126 bp QIAGEN GmbH, Hilden, Germany
RDH10 QT00029176 107 bp QIAGEN GmbH, Hilden, Germany
SPINK7 QT00039585 126 bp QIAGEN GmbH, Hilden, Germany
STRA6 QT00006748 74 bp QIAGEN GmbH, Hilden, Germany
TBP QT00000721 132 bp QIAGEN GmbH, Hilden, Germany
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Figure A1. qRT-PCR analysis of ADH7, ALDH1A1, RBP1, RDH10, and CRABP2 transcripts in pri-
mary limbal epithelial cells (LEC) treated with retinol (Ret), all trans-retinoic acid (at-RA), AGN 
193109 (AGN), or UVI 3003 (UVI), for 24 h and 48 h, respectively. The transcripts shown here are 
related to retinoic acid pathways (from literature search) and were found to be deregulated in the 
conjunctiva of aniridia patients [9]. ADH7 showed a tendency for downregulation after the 48 h 
treatment with 1 µM Ret or at-RA. The 1.5 µM AGN treatment for 24 h led to the upregulation of 
ADH7 (FC = 3.5). The 1.0 µM and 1.5µM UVI treatment for 24 h also led to a significant upregulation 
of ADH7 (FC = 4.9 and FC = 7.9). ADLH1A was not significantly affected by any of the treatments. 
RBP1 showed significant upregulation after Ret treatment for 48 h using the 1 µM (FC = 1.6) and 5 
µM (FC = 1.8) concentration. RDH10 was upregulated after the 5 µM RA treatment for 48 h (FC = 
2.6). AGN treatment also led to upregulation using the 1.5 µM concentration for 24 h (FC = 3.2) and 
48 h (FC = 1.9). CRABP2 was significantly downregulated after the 48 h Ret treatment with the 1 µM 
(FC = 0.6) and at 5 µM concentrations (FC = 0.6). The 5 µM RA treatment for 48 h led to the down-
regulation of CRABP2 (FC = 0.3). AGN treatment led to CRABP2 upregulation after the 24 h treat-
ment with 1.0 µM (FC = 1.5) and after the 48 h treatment with the t0.5 µM concentrations (FC = 2.4). 
UVI treatment led to significant CRABP2 downregulation after 24 h using the1.5 µM (FC = 0.5) con-
centrations and after 48 h for all of the used concentrations (FC = 0.5–0.2). * p ≤ 0.05; ** p ≤ 0.01; *** p 
≤ 0.001; n = 3. 
Figure A1. qRT-PCR analysis of ADH7, ALDH1A1, RBP1, RDH10, and CRABP2 transcripts in
primary limbal epithelial cells (LEC) treated with retinol (Ret), all trans-retinoic acid (at-RA),
AGN 193109 (AGN), or UVI 3003 (UVI), for 24 h and 48 h, respectively. The transcripts shown
here are related to retinoic acid pathways (from literature search) and were found to be der gu-
lated in the co junctiva of aniridia patients [9]. ADH7 showed a te dency for downr gulation
after the 48 h treatment with 1 µM Ret or at-RA. The 1.5 µM AGN treatment for 24 h led to
the upregulation of ADH7 (FC = 3.5). The 1.0 µM and 1.5µM UVI treatment for 24 h also led
to a significant upregulation of ADH7 (FC = 4.9 and FC = 7.9). ADLH1A was not significantly
affected by any of the treatments. RBP1 showed significant upregulation after Ret treatment
for 48 h using the 1 µM (FC = 1.6) and 5 µM (FC = 1.8) concentration. RDH10 was upregu-
lated after the 5 µM RA treatment for 48 h (FC = 2.6). AGN treatm nt also led to upr gulation
using the 1.5 µM concentration for 24 h (FC = 3.2) and 48 h (FC = 1.9). CRABP2 was signifi-
cantly downregulated after the 48 h Ret treatment with the 1 µM (FC = 0.6) and at 5 µM con-
centrations (FC = 0.6). The 5 µM RA treatment for 48 h led to the downregulation of CRABP2
(FC = 0.3). AGN treatment led to CRABP2 upregulation after the 24 h treatment with 1.0 µM
(FC = 1.5) and after the 48 h treatment with the t0.5 µM concentrations (FC = 2.4). UVI treatment led
to significant CRABP2 downregulation after 24 h using the1.5 µM (FC = 0.5) concentrations and after
48 h for all of the used concentrations (FC = 0.5–0.2). * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; n = 3.
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Figure A2. qRT-PCR analysis of ELOVL7, FABP5, and PPARG transcripts in primary limbal epithelial cells (LEC) treated 
with retinol (Ret), all trans-retinoic acid (at-RA), AGN 193109 (AGN), or UVI 3003 (UVI), for 24 h and 48 h, respectively. 
The transcripts shown here are related to retinoic acid pathways (from literature search) and were found to be deregulated 
in the conjunctiva of aniridia patients [9]. ELOVL7 was upregulated after the 24 h RA treatment using the t0.5 µM (FC = 
1.6) and 1.5 µM concentrations (FC = 1.6). Higher AGN concentrations, such as the 1.5 µM concentration for 24 h (FC = 7.4) 
or 1.5 µM for 48 h (FC = 6.5), led to the upregulation of ELOVL7. UVI treatment for 24 h using the 1.5 µM (FC = 5) concen-
tration led to an upregulation of ELOVL7 expression. FABP5 expression was upregulated after 24 h AGN treatment with 
1.0 µM (FC = 1.6) and 1.5 µM concentrations (FC = 1.6). PPARG showed downregulation after 5 µM Ret treatment for 48 
h (FC = 0.7). The 1.0 µM and 1.5 µM AGN treatment for 24 h (FC = 2.7 and FC = 4.6) led to PPARG upregulation. After 1.5 
µM AGN treatment for 48 h, an upregulation of PPARG was observed (FC = 5.6). * p≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; n = 3. 
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with retinol (Ret), ll i (at- ), AGN 193109 (AGN), or UVI 3003 (UVI), for 24 h and 48 h, respectively. The
transcripts shown here a relat d o retinoic acid pathways (from literatu e search) and were found to be der gulated in the
conjunctiva of aniridia patients [9]. ELOVL7 was upregulated after the 24 h RA treatment using the t0.5 µM (FC = 1.6) and
1.5 µM concentrations (FC = 1.6). Higher AGN concentrations, such as the 1.5 µM concentration for 24 h (FC = 7.4) or 1.5 µM
for 48 h (FC = 6.5), led to the upregulation of ELOVL7. UVI treatment for 24 h using the 1.5 µM (FC = 5) concentration led to
an upregulation of ELOVL7 expression. FABP5 expression was upregulated after 24 h AGN treatment with 1.0 µM (FC = 1.6)
and 1.5 µM concentrations (FC = 1.6). PPARG showed downregulation after 5 µM Ret treatment for 48 h (FC = 0.7). The
1.0 µM and 1.5 µM AGN treatment for 24 h (FC = 2.7 and FC = 4.6) led to PPARG upregulation. After 1.5 µM AGN treatment
for 48 h, an upregulation of PPARG was observed (FC = 5.6). * p≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; n = 3.
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